This protocol addresses leprosy classified as multibacillary (MB) — determined by the number of skin lesions, the presence of nerve involvement, and the identification of bacilli on slit-skin smear.
Leprosy is classified as paucibacillary (PB) or multibacillary (MB) based on the number of skin lesions, presence of nerve involvement, and identification of bacilli on slit-skin smear. The MB classification carries specific therapeutic implications distinct from PB disease.
MB leprosy is managed with a multi-drug combination regimen. The complete protocol — covering all agents involved and the full treatment course — is available via the structured protocol below.
Leprosy is classified as paucibacillary (PB) or multibacillary (MB), based on the number of skin lesions, presence of nerve involvement and identification of bacilli on slit-skin smear.
The guidelines recommend a 3-drug regimen of rifampicin, dapsone and clofazimine for all leprosy patients, with a duration of treatment of 6 months for PB leprosy and 12 months for MB leprosy.
The same 3-drug regimen of rifampicin, dapsone and clofazimine may be used for all leprosy patients, with a duration of treatment of 6 months for PB leprosy and of 12 months for MB leprosy.
View source ↗